(VIANEWS) - National Energy Services Reunited Corp. (NESR), Johnson & Johnson (JNJ), Masimo Corporation (MASI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. National Energy Services Reunited Corp. (NESR)
27.3% sales growth and 4.95% return on equity
National Energy Services Reunited Corp. provides oilfield services to oil and gas companies in the Middle East, North Africa, and the Asia Pacific regions.
National Energy Services Reunited Corp.'s sales growth this year is expected to be 15.7% and 22.2% for next year.
Year-on-year quarterly revenue growth grew by 15.6%, now sitting on 878.95M for the twelve trailing months.
Volume
Today's last reported volume for National Energy Services Reunited Corp. is 456345 which is 48.92% above its average volume of 306425.
National Energy Services Reunited Corp.'s sales growth for the next quarter is 27.3%. The company's growth estimates for the present quarter and the next is a negative 25% and 15%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.95%.
Volatility
National Energy Services Reunited Corp.'s last day, last week, and last month's current volatility was 2.00%, 2.94%, and 1.75%, respectively.
National Energy Services Reunited Corp.'s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.70% (day), 3.20% (last week), and 3.55% (last month), respectively.
National Energy Services Reunited Corp.'s Stock Yearly Top and Bottom Value
National Energy Services Reunited Corp.'s stock is valued at $12.77 at 01:22 EST, way below its 52-week high of $15.95 and way above its 52-week low of $6.20.
National Energy Services Reunited Corp.'s Moving Average
National Energy Services Reunited Corp.'s value is way above its 50-day moving average of $11.53 and above its 200-day moving average of $12.74.2. Johnson & Johnson (JNJ)
10.4% sales growth and 26.81% return on equity
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide.
Johnson & Johnson's sales growth this year is expected to be 14.1% and 4% for next year.
Year-on-year quarterly revenue growth grew by 27.1%, now sitting on 89.19B for the twelve trailing months.
Volume
Today's last reported volume for Johnson & Johnson is 8568560 which is 44.25% above its average volume of 5939880.
Johnson & Johnson's sales growth is a negative 0% for the present quarter and 10.4% for the next. The company's growth estimates for the current quarter and the next is 7.3% and 19.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.81%.
Volatility
Johnson & Johnson's last day, last week, and last month's current volatility was 0.64%, 2.02%, and 0.97%, respectively.
Johnson & Johnson's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.07% (day), 1.41% (last week), and 1.12% (last month), respectively.
Johnson & Johnson's Stock Yearly Top and Bottom Value
Johnson & Johnson's stock is valued at $160.47 at 01:22 EST, way under its 52-week high of $179.92 and way higher than its 52-week low of $133.65.
Johnson & Johnson's Moving Average
Johnson & Johnson's worth is below its 50-day moving average of $170.32 and under its 200-day moving average of $167.60.Previous days news about Johnson & Johnson(JNJ)
- According to Bloomberg Quint on Thursday, 30 September, "Covax also pointed to challenges at manufacturing sites that have affected supply of the Johnson & Johnson and AstraZeneca Plc vaccines."
- According to MarketWatch on Wednesday, 29 September, "If preventing severe disease is the nation's ", and Johnson & Johnson do a great job at keeping most people out of the hospital and from dying."
- According to Bloomberg Quint on Wednesday, 29 September, "Trillium itself has pressed companies such as Johnson & Johnson and Starbucks Corp. on issues such as performing racial audits and reducing plastics use. "
- According to MarketWatch on Thursday, 30 September, "AstraZeneca is planning to apply for full approval of the vaccine from the U.S. Food and Drug Administration later this fall, rather than seek emergency-use authorization, the company said in July, and Johnson & Johnson and has extended full approval to the one developed by Pfizer with German partner BioNTech ."
3. Masimo Corporation (MASI)
7.4% sales growth and 16.35% return on equity
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide.
Masimo Corporation's sales growth this year is expected to be 6.4% and 9.4% for next year.
Year-on-year quarterly revenue growth grew by 1.4%, now sitting on 1.18B for the twelve trailing months.
Volume
Today's last reported volume for Masimo Corporation is 237766 which is 4.01% below its average volume of 247701.
Masimo Corporation's sales growth for the next quarter is 7.4%. The company's growth estimates for the ongoing quarter and the next is 13.7% and 11.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.35%.
Volatility
Masimo Corporation's last day, last week, and last month's current volatility was 0.53%, 1.64%, and 1.01%, respectively.
Masimo Corporation's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.17% (day), 2.53% (last week), and 2.03% (last month), respectively.
Masimo Corporation's Stock Yearly Top and Bottom Value
Masimo Corporation's stock is valued at $270.43 at 01:22 EST, below its 52-week high of $288.27 and way higher than its 52-week low of $205.10.
Masimo Corporation's Moving Average
Masimo Corporation's value is below its 50-day moving average of $274.85 and above its 200-day moving average of $247.45.4. Royalty Pharma (RPRX)
6.2% sales growth and 19.76% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is expected to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 2.24B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 1096430 which is 55.78% below its average volume of 2479860.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the current quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.76%.
Volatility
Royalty Pharma's last day, last week, and last month's current volatility was 0.25%, 2.14%, and 1.32%, respectively.
Royalty Pharma's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.09% (day), 2.00% (last week), and 2.53% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $36.23 at 01:22 EST, way under its 52-week high of $53.23 and above its 52-week low of $34.80.